Patents by Inventor Ugur Sahin

Ugur Sahin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230303656
    Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
    Type: Application
    Filed: June 13, 2023
    Publication date: September 28, 2023
    Inventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
  • Publication number: 20230295335
    Abstract: The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
    Type: Application
    Filed: March 15, 2023
    Publication date: September 21, 2023
    Inventors: Andreea IOAN, Esther Cornelia Wilhelmina BREIJ, Lars GUELEN, David P.E. SATIJN, Ugur SAHIN, Alexander MUIK, Kristina SCHÖDEL, Sina FELLERMEIER-KOPF, Bart-Jan DE KREUK, Richard HIBBERT, Janine SCHUURMAN, Aran Frank LABRIJN
  • Publication number: 20230287088
    Abstract: The present disclosure relates to a binding agent comprising a first and a second binding domain, wherein the first binding domain is capable of binding to a coronavirus spike protein (S protein) and the second binding domain is capable of binding to the coronavirus S protein, and wherein the first and second binding domains bind to different epitopes of the coronavirus S protein. Moreover, the disclosure relates to an antibody capable of binding to a coronavirus spike protein (S protein). The disclosure also relates to a nucleic acid such as RNA encoding the binding agent, in particular antibody, disclosed herein and a host cell transformed or transfected with said nucleic acid. Furthermore, the disclosure relates to a medical use of said binding agent, antibody, or nucleic acid. The agents and medical uses described herein are, in particular, useful for the prevention or treatment of coronavirus infection in a subject.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 14, 2023
    Inventors: Karsten Beckmann, Anna Carle, Sandra Prassl, Claudia Paulmann, Christiane Stadler, Georg Falck, Leyla Fischer, Alexander Muik, Ugur Sahin, Caroline Scharf
  • Publication number: 20230270878
    Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: August 31, 2023
    Inventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
  • Publication number: 20230272406
    Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.
    Type: Application
    Filed: September 28, 2022
    Publication date: August 31, 2023
    Inventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov
  • Publication number: 20230265454
    Abstract: The present invention embraces an RNA replicon (self-amplifying RNA vector (saRNA)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. According to the invention, translation of the replicase open reading frame is uncoupled from a 5?-terminal cap by placing translation of the replicase open reading frame under the translational control of an internal ribosome entry site (IRES). Thereby the initiation of translation depends on the molecular properties of the respective IRES, which compared to cap-dependent translation may require less or no cellular initiation factors to direct the ribosome to the translational start site. According to the invention, IRES-controlled replicase translation may allow the use of uncapped synthetic saRNA. Furthermore, the use of an IRES provides for the option to insert additional transgenes upstream to the IRES.
    Type: Application
    Filed: June 1, 2021
    Publication date: August 24, 2023
    Inventors: Mario Perkovic, Sonja Witzel, Tim Beissert, Ugur Sahin
  • Publication number: 20230226217
    Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
    Type: Application
    Filed: November 30, 2022
    Publication date: July 20, 2023
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
  • Publication number: 20230212301
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: November 14, 2022
    Publication date: July 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel
  • Publication number: 20230201817
    Abstract: A portable system for producing a formulation comprising lipid nanoparticle (LNP)-encapsulated RNA includes: a first sub-system comprising multiple drug substance formulation modules, the first sub-system comprising: a transcription module for forming an RNA solution via in vitro transcription; and a second sub-system operatively downstream of the first sub-system comprising multiple drug product formation modules, the second sub-system comprising: an LNP formulation module for producing a first RNA-LNP preparation from the RNA solution, wherein each of the transcription module and the LNP formulation module is contained within a separate standard shipping container.
    Type: Application
    Filed: December 20, 2022
    Publication date: June 29, 2023
    Inventors: Christian Reinsch, David Estapé Izquierdo, Sierk Poetting, Ugur Sahin, Alexander Muik, Asaf Poran, Martin Lang, Oliver Hennig, Karsten Pietron-Kattmann, Manfred Brunen, Rainer Kröner, Mario Büttner, Sven Stegmann, Kristin Hoffmann
  • Publication number: 20230193296
    Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
    Type: Application
    Filed: October 25, 2022
    Publication date: June 22, 2023
    Inventors: Ugur Sahin, Silke Holtkamp, Ozlem Tureci, Sebastian Kreiter
  • Publication number: 20230193261
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Application
    Filed: August 24, 2022
    Publication date: June 22, 2023
    Inventors: Ugur Sahin, Özlem Tureci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Woll, Gabriela-Elena Oprea
  • Publication number: 20230190898
    Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.
    Type: Application
    Filed: October 12, 2022
    Publication date: June 22, 2023
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
  • Patent number: 11673939
    Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: June 13, 2023
    Inventors: Ugur Sahin, Bonny Gaby Lui, Nadja Salomon, Joycelyn Wüstehube-Lausch, Matin Daneschdar, Hans-Ulrich Schmoldt, Markus Fiedler
  • Patent number: 11660338
    Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: May 30, 2023
    Assignees: BIONTECH SE, TRON
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefesha
  • Publication number: 20230145774
    Abstract: The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immunostimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.
    Type: Application
    Filed: March 30, 2021
    Publication date: May 11, 2023
    Inventors: Ugur SAHIN, Lena Mareen KRANZ, Mustafa DIKEN, Lina HILSCHER, Sebastian KREITER
  • Publication number: 20230119334
    Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.
    Type: Application
    Filed: August 21, 2022
    Publication date: April 20, 2023
    Inventors: Ralf Holger VOSS, Ugur SAHIN, Matthias THEOBALD, Petra SIMON, Matthias BIRTEL
  • Publication number: 20230117803
    Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by co-administering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.
    Type: Application
    Filed: February 2, 2021
    Publication date: April 20, 2023
    Inventors: Ugur SAHIN, Alexander MUIK, Lena KRANZ, Mathias VORMEHR
  • Patent number: 11628209
    Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 18, 2023
    Assignees: Tron GGMBH, BioNTech SE
    Inventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Petra Simon, Christoph Hartmann, Stefanie Hubich, Thomas Bukur, Thorsten Litzenberger
  • Publication number: 20230114808
    Abstract: Disclosed herein are compositions, uses, and methods for treatment of prostate cancers.
    Type: Application
    Filed: March 11, 2020
    Publication date: April 13, 2023
    Inventors: David WEBER, Carina WALTER, Diana BAREA ROLDAN, Ruprecht KUNER, Elif DIKEN, Martin SUCHAN, Stefania GANGI MAURICI, Ugur SAHIN
  • Publication number: 20230109496
    Abstract: The present invention relates to antibodies capable of binding to human CD27 and to variants thereof comprising a modified Fc region comprising one or more mutations that enhances the Fc-Fc interaction of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Application
    Filed: September 6, 2022
    Publication date: April 6, 2023
    Inventors: Andreea Ioan, Frank Beurskens, Rob N. de Jong, Janine Schuurman, Esther C. W. Breij, Isil Altintas, Pauline L. de Goeje, David Satijn, Peter Boross, Ugur Sahin, Friederike Gieseke, Alexander Muik, Kristina Schödel